---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021748"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:23:30.232396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q3 revenue $1.2M, loss $0.10/share; key Medicare coverage step from unanimous CAC expert support

## Summary
- Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.
- GAAP net loss $10.4M ($0.10/share); non-GAAP adjusted loss $10.3M ($0.10/share).
- Cash $47.3M after $27M public offering; runway extended through 2026.
- MolDx CAC meeting on Sept 4: medical experts unanimously supported Medicare coverage for EsoGuard.
- Appointed Danielle Scelfo as SVP Market Access to lead payor engagement and coverage expansion.

## SEC filing metadata
- accession: 0001493152-25-021748
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315225021748/0001493152-25-021748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315225021748/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021748
- JSON: https://secwatch.observer/filing/0001493152-25-021748.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.